Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

GeneDx Holdings Corp.

Notice of Proposed Sale

Filed Sep 1, 2026Accepted Sep 1, 2026, 6:06 PM EDTFiling CIK 1944119Accession 0001628280-26-059939
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
GeneDx Holdings Corp.
Issuer CIK
0001818331
SEC file number
001-39482
Phone
888-729-1206
Person for whose account securities are to be sold
Kevin Feeley
Relationships to issuer
Officer
Street
333 Ludlow St, North Tower
Street (continued)
6th Floor
City
Stamford
State / country code
CT
Postal code
06902

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Class A Common Stock5,410458,50029,822,54109/01/2026NASDAQMorgan Stanley Smith Barney

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney
Street
2000 Westchester Avenue
City
Purchase
State / country code
NY
Postal code
10577

Acquisition of securities to be sold

Acquisition of securities to be sold · 3 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Class A Common Stock09/01/2022Acquired as compensation - Restricted Stock UnitsIssuer372N09/01/2022Compensation
Class A Common Stock12/09/2022Acquired as compensation - Restricted Stock UnitsIssuer1,284N12/09/2022Compensation
Class A Common Stock04/26/2023Acquired as compensation - Restricted Stock UnitsIssuer3,754N04/26/2023Compensation

Sales reported in the preceding three months

Sales reported in the preceding three months · 3 reported rows
SellerSecuritySale dateAmount soldGross proceeds
Kevin FeeleyClass A Common Stock06/01/202636919,092
Kevin FeeleyClass A Common Stock06/09/20261,26668,073
Kevin FeeleyClass A Common Stock06/16/20263,729226,597

Seller — prior-sale row 1, entry 1

Name
Kevin Feeley
Street
333 Ludlow St, North Tower
Street (continued)
6th Floor
City
Stamford
State / country code
CT
Postal code
06902

Seller — prior-sale row 2, entry 1

Name
Kevin Feeley
Street
333 Ludlow St, North Tower
Street (continued)
6th Floor
City
Stamford
State / country code
CT
Postal code
06902

Seller — prior-sale row 3, entry 1

Name
Kevin Feeley
Street
333 Ludlow St, North Tower
Street (continued)
6th Floor
City
Stamford
State / country code
CT
Postal code
06902

Prior-sale reporting

Nothing to report for the preceding three months
N

Remarks

Represents approximately 5,410 shares to be sold on behalf of the Reporting Person, including 1) 372 shares to be sold in connection with anticipated vesting of RSUs on September 1, 2026; 2) approximately 1,284 shares to be sold in connection with anticipated vesting of RSUs on September 9, 2026; and 3) approximately 3,754 shares to be sold in connection with anticipated vesting of RSUs on September 16, 2026. Shares sold in the past 3 months by the Reporting Person include 5,364 shares sold to cover tax withholding obligations in connection with vesting and settlement of RSUs.

Notice signature

Notice date
09/01/2026
Signed
/s/ Kevin Feeley

Company context

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity ™ - the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx ™ and GenomeDx ® tests - ranked #1 by expert geneticists and granted FDA Breakthrough Device designation - enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Current securities

Historical securities (8)

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureNov 18, 2026
  2. SCHEDULE 13G/A - filed by ARK Investment Management LLC regarding GeneDx Holdings Corp.Nov 13, 2026
  3. 10-Q filingNov 9, 2026
  4. Results of Operations and Financial ConditionNov 9, 2026
  5. SCHEDULE 13G - filed by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC regarding GeneDx Holdings Corp.Nov 6, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.